Overview

A Safety Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients in Combination With Carboplatin, Etoposide and Tislelizumab

Status:
Not yet recruiting

Trial end date:
2025-06-16

Target enrollment:

Participant gender:

Summary

This study aims to establish a safe and well tolerated dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide, and tislelizumab in induction treatment and with tislelizumab in maintenance treatment in newly diagnosed patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
Carboplatin
Etoposide
Lutetium Lu 177 dotatate